News | October 01, 2008

Findings From Sex, Gender Symposium Help Advance Development of Treatments for Vascular Diseases

October 2, 2008 - The Impact of Sex and Vascular Diseases and Implications for Therapies symposium conducted in February at Cedars-Sinai Medical Center in Los Angeles uncovered a series of knowledge gaps related to the sex differences in vascular disease, its symptoms, risk factors and response to treatment.

The first-of-its-kind scientific symposium exploring sex-based medicine's impact on the treatment of a wide array of vascular diseases was co-chaired by Noel Bairey Merz M.D. and Saralyn Mark M.D, The conference brought together a renowned panel of physicians and clinical research scientists to devise a plan of action to address the significant discrepancies existing between men and women in the prevention, diagnosis and treatment of vascular disease.

Conference recommendations could make a significant impact on the healthcare industry ranging from clinical trials to the development of medical technology and therapies. Preliminary findings reveal that the basic biological make up of the heart and blood vessels differs significantly between men and women and may have a direct and dramatic impact on the prevention, diagnosis and treatment of heart attacks, strokes and other forms of vascular disease. Symposium faculty also report reproductive hormones such as estrogen heavily influence the progression and treatment of vascular disease.

The symposium’s panel of experts identified seven key preliminary findings that address the inherent differences between men and women that could redefine sex-based medicine and research methodology in vascular disease. The seven key findings include:

- Sex Differences in Cardiovascular Disease: A knowledge gap exists in the understanding of male and female patterns of cardiovascular disease, symptoms and response to treatment. The differences must be incorporated into all aspects of future research including drug therapy and medical device development.

- Sex Differences in Clinical Research: The predominant pattern in clinical trials is to combine males and females regardless of the potential sex differences. To advance vascular medicine, clinical research methodology must incorporate sex differences when evaluating responses to treatments and test performance. In addition, there is a general failure to note women’s hormonal status (i.e., premenopausal or postmenopausal) when evaluating their responses to testing—a situation that needs to be rectified.

- Sex Differences Applied to Research Study Design: The role of sex should not be limited to specifying the number of women enrolled in a study. Methodology needs to include the comparison of females to males; how study design identifies sex differences; and how results are interpreted relative to sex.

- Sex Differences and Interdisciplinary Research: In general, national conferences, scientific meetings and research investigators tend to focus on a particular, isolated area of research. By contrast, interdisciplinary gatherings can identify collaborative areas of study and investigation.

0. Sex Differences in Regenerative Medicine: Sex differences in regenerative medicine suggest that female stem cells, when infused with male stem cells, support tissue regeneration, whereas male stem cells alone are less successful. More research is needed to understand what appears to make female stem cells superior in this application.
0. Sex Differences and the Role of Reproductive Hormones: While it is clear that hormones such as estrogen have an impact on processes throughout the body, more study is needed to better understand and identify how hormones impact heart rate, blood pressure and other body processes, and particularly how they affect vascular disease.

- Sex Differences in Cellular Environment: Advances in biology underscore the message that cellular environment must be conducive for the growth and function of the cell. Investigation designed to identify optimal surfaces to attract the growth of healthy endovascular cells needs to be a priority for further research.

“The goal of the symposium was to address the increasingly alarming discovery that women do not appear to be receiving maximum benefit from our current strategies for cardiovascular disease (CVD),” said Dr. Bairey Merz. “A recent publication showed that while overall CVD has declined by 52 percent in men and 49 percent in women, there is an actual increase in CVD related deaths in younger, middle-aged women, despite increased overall use of diagnostic procedures and preventative medications.”

“Vascular disease is the leading killer of both men and women and yet little knowledge exists with regard to how sex differences impact the development of these conditions,” said Dr. Mark. “These preliminary findings are a significant step toward eliminating the knowledge gaps in vascular health and ideally will eventually change how the medical and pharmaceutical industries identify and evaluate the sex-based discrepancies in the diagnosis and treatment of vascular disease.”

Sponsored by Cook Medical, symposium participants included Drs. Leslee Shaw, Prediman K. Shah, Barbara Boyan, Doris Taylor, Noel Bairey Merz, Alice Jacobs and Eduardo Marban. Representatives of the Organization for the Study of Sex Differences (OSSD), the American College of Cardiology (ACC), and the National Heart, Lung and Blood Institute (NHLBI) also participated.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init